Moderna's strong move towards COVID-19 vaccination
17/11/20 -"Against the background of Moderna's recent positive announcement that its vaccine candidate mRNA-1273 generated 94.5% efficacy in a phase III trial, we have abandoned our cautious stance on the ..."
Pages
66
Language
English
Published on
17/11/20
You may also be interested by these reports :
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...
08/06/26
Anticipated sales are now even more skewed toward 2H, with HSD growth expected in 1H. We also record a CHF15m decrease in Building K sales in 2026, ...
04/06/26
Over the 5 days to 02-06, 18 pharma stocks out of the 23 under coverage fell. The sector performance chart is not looking good. We see an opportunity ...